Pharvaris ( (PHVS) ) just unveiled an update.
On April 7, 2025, Pharvaris announced its financial results for the fourth quarter and full year of 2024, alongside a business update. The company achieved target enrollment in its RAPIDe-3 Phase 3 study for the on-demand treatment of HAE attacks, and is progressing with enrollment in the CHAPTER-3 study for prophylaxis of HAE attacks, with topline data expected in the second half of 2026. Deucrictibant, their lead product, received orphan medicinal product designation in Europe, reinforcing its potential impact on treating bradykinin-mediated angioedema. Pharvaris maintains a strong financial position with €281 million in cash and cash equivalents as of December 31, 2024, despite increased R&D and administrative expenses.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, (PHVS) is a Neutral.
Pharvaris faces significant financial challenges typical for a pre-revenue biotech firm, with substantial operating losses and negative cash flow. The technical analysis indicates neutral momentum, with valuation reflecting high risk. Lack of detailed earnings guidance adds to uncertainty.
To see Spark’s full report on (PHVS) stock, click here.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company aims to provide effective and convenient oral therapies for preventing and treating these conditions.
YTD Price Performance: -22.98%
Average Trading Volume: 42,975
Technical Sentiment Signal: Strong Buy
Current Market Cap: $771.2M
See more data about PHVS stock on TipRanks’ Stock Analysis page.